Related Experiment Video
Updated: Jun 6, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Chronic Hepatitis D Virus Infection and Its Treatment: A Narrative Review
Poonam Mathur1, Arshi Khanam1, Shyam Kottilil1
1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Insights
Hepatitis D virus (HDV) infection is severe, accelerating liver disease. New antivirals, like buleviritide and lonafarnib, show promise in combination with pegylated interferon (PEG-IFN) for better HDV suppression.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Hepatitis D virus (HDV) infection is the most severe form of viral hepatitis, necessitating hepatitis B virus (HBV) co-infection.
- HDV infection accelerates liver disease progression, leading to cirrhosis and hepatocellular carcinoma.
- Current treatments lack reliable HDV eradication and have limited efficacy and tolerability.
Purpose of the Study:
- To discuss the characteristics of HDV infection.
- To review existing and novel antiviral therapies for HDV.
- To highlight the potential of new agents in combination therapy.
Main Methods:
- Review of current literature on HDV infection and its management.
- Analysis of the mechanisms of action for novel antiviral therapies.
- Discussion of clinical trial data for emerging HDV treatments.
Main Results:
- Pegylated interferon (PEG-IFN) is the only approved treatment, suppressing HDV RNA but with low cure rates and adverse effects.
- Newer antivirals targeting HDV entry (bulevirtide), assembly (lonafarnib), and export (REP-2139) show promising results.
- Combination therapies with PEG-IFN and novel agents aim for improved long-term HDV RNA suppression.
Conclusions:
- Effective and tolerable treatments for chronic HDV infection are urgently needed.
- Emerging antiviral therapies offer new hope for managing HDV infection.
- Combination strategies may be key to achieving sustained viral suppression and improving patient outcomes.
Abstract:
More than 12 million individuals worldwide are chronically infected with the hepatitis D virus (HDV). HDV infection is the most severe form of viral hepatitis since it requires hepatitis B virus co-infection and accelerates progression to cirrhosis and hepatocellular carcinoma. Therefore, treatment modalities to slow the progression of the disease are essential but not yet available. In addition, no antiviral treatment to date has been shown to reliably eradicate HDV. Pegylated interferon (PEG-IFN) is the only universally used treatment to suppress HDV RNA replication and improve liver inflammation and fibrosis. This treatment can be completed in 12-18 months, but cure rates remain low, and success does not reliably increase with the addition of a nucleos(t)ide analog. PEG-IFN therapy is also limited by poor tolerability and multiple adverse effects, including neutropenia, thrombocytopenia, and neuropsychiatric symptoms. Newer antiviral therapies in development target unique aspects of HDV viral replication and show promising results in combination with PEG-IFN for long-term HDV RNA suppression. These newer antiviral therapies include buleviritide (which blocks HDV entry), lonafarnib (which prevents HDV assembly), and REP-2139 (which prevents HDV export). In this manuscript, we discuss the characteristics of HDV infection and review the new antiviral therapies approved for treatment and those under investigation.
More Related Videos
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Retrovirus Life Cycles
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

